Study (reference) | n | M. follow-up (vrs) | Risk | HDR schedule | ADT | Toxicity score | G2 GI late toxicity | G3 GI late toxicity | G2 GU late toxicity | G3 GU late toxicity | bRFS* |
---|---|---|---|---|---|---|---|---|---|---|---|
Demanes (1) | 298 | 5.2 | L 81%, I 18%, H 1% | 6 × 7 Gy (53%) | 24% | CTCAE 3.0 | <1% | <1% | 10% | 3% | 97% |
4 × 9.5 Gy (47%) | |||||||||||
Zamboglou (2) | 718 | 4.4 | L 55%, I 25%, H 20% | 4 × 9.5 Gy (68%) | 21.4% | CTCAE 3.0 | ~1% | 1.6% | ~20% | 3.5% | 94% |
3 × 11.5 Gy (32%) | |||||||||||
Yoshioka (3) | 112 | 5.4 | L 13%, I 26%, H 61% | 9 × 6 Gy | 84% | CTCAE 3.0 | 12%# | 3%# | 12%# | 3%# | 83% |
Hoskin (4) | 197 | 0.5-5 | L 4%, I 52%, H 44% | 4 × 8.5 Gy (15%) | 80% | RTOG | 1% | 4-13% | 20-30% | 3-14% | 95% |
4 × 9 Gy (13%) | |||||||||||
3 × 10.5 Gy (55%) | |||||||||||
2 × 13 Gy (17%) | |||||||||||
Rogers (5) | 284 | 2.7 | I 100% | 6 × 6.5 Gy | 16% | RTOG | 0% | 0% | 1.8% | 0.7% | 83% |
Present study | 36 | 6.9 | L 78%, I 22% | 4 × 9,5 Gy | 14% | CTCAE 3.0 | 0% | 0% | 28% | 19% | 97% |